Literature DB >> 11392627

Anticholinergic therapy for airway diseases.

D B Jacoby1, A D Fryer.   

Abstract

Anticholinergics are commonly used in the treatment of airway diseases. While their effectiveness in chronic asthma offers no advantage over beta-agonists, evidence continues to accumulate suggesting substantial additional benefit in acute asthma attacks. This increased response to anticholinergics suggest that cholinergic bronchoconstriction is increased in acute asthma. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392627     DOI: 10.1016/s0024-3205(01)01053-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Neurotransmitters in airway parasympathetic neurons altered by neurotrophin-3 and repeated allergen challenge.

Authors:  Jenny Pan; Holly K Rhode; Bradley J Undem; Allen C Myers
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

2.  Lung eosinophils increase vagus nerve-mediated airway reflex bronchoconstriction in mice.

Authors:  Zhenying Nie; Jessica N Maung; David B Jacoby; Allison D Fryer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-20       Impact factor: 5.464

3.  Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways.

Authors:  Melanie Pfaff; Norbert Powaga; Sibel Akinci; Werner Schütz; Yoshiko Banno; Silke Wiegand; Wolfgang Kummer; Jürgen Wess; Rainer Viktor Haberberger
Journal:  Respir Res       Date:  2005-05-31

Review 4.  Bulbus Fritillariae Cirrhosae as a Respiratory Medicine: Is There a Potential Drug in the Treatment of COVID-19?

Authors:  Yunyun Quan; Li Li; Zhujun Yin; Shilong Chen; Jing Yi; Jirui Lang; Lu Zhang; Qianhua Yue; Junning Zhao
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

Review 5.  Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling.

Authors:  Andrew B Tobin; Adrian J Butcher; Kok Choi Kong
Journal:  Trends Pharmacol Sci       Date:  2008-07-06       Impact factor: 14.819

Review 6.  Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors.

Authors:  Hong-Tao Xiao; Zhi Liao; Rong-Sheng Tong
Journal:  Drug Des Devel Ther       Date:  2012-11-01       Impact factor: 4.162

Review 7.  Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.

Authors:  Jun Zhong; Michael Roth
Journal:  Ther Clin Risk Manag       Date:  2014-06-13       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.